SCHEMBL170139

SCHEMBL170139

Oc1cc2cccnc2c2cccnc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.59
KDM4E B2RXH2 12/20 0.56
L3MBTL1 Q9Y468 8/20 0.54
NPC1 O15118 6/20 0.54
RAB9A P51151 5/20 0.54
METAP2 P50579 2/20 0.53
METAP1 P53582 2/20 0.53
MMP2 P08253 1/20 0.53
CHRM1 P11229 1/20 0.53
TSHR P16473 1/20 0.53
COMT P21964 1/20 0.53
ADRA1A P35348 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HTT P42858 3/20 0.52
LMNA P02545 3/20 0.52
CCR1 P32246 2/20 0.52
CCR8 P51685 2/20 0.52
HSP90AA1 P07900 2/20 0.52
MAPT P10636 2/20 0.52
MPI P34949 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1302713 0.90 TRPM4 (0.55) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL28229074 0.90 ALDH1A1 (0.62) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL169518 0.84 L3MBTL1 (0.61) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL29683521 0.84 L3MBTL1 (0.61) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL13313353 0.83 KDM4E (0.48) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL13271167 0.83 OPRK1 (0.49) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL13271283 0.83 ALDH1A1 (0.54) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL1408764 0.82 TRPM4 (0.55) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL13271168 0.79 ERN1 (0.48) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL13313351 0.79 KDM4E (0.44) ALDH1A1KDM4EL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8652752-B2 Sulphonium salt initiators BASF SE (DE) 2014-02-18 US claimed
EP-2197840-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-11-06 EP claimed
US-20100297540-A1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2010-11-25 US claimed
EP-2197869-A1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2010-06-23 EP claimed
WO-2009047105-A1 SULPHONIUM SALT INITIATORS BASF SE (CH) 2009-04-16 WO claimed
CN-118307514-A Organic electroluminescent compound and organic electroluminescent device comprising the same 罗门哈斯电子材料韩国有限公司 2024-07-09 CN disclosed
WO-2024120466-A1 MONOSACCARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS SURIO THERAPEUTICS CO., LTD (CN) 2024-06-13 WO disclosed
WO-2024120442-A1 PAK4 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CONVERGEN (SUZHOU) PHARMACEUTICAL CO., LTD. (CN) 2024-06-13 WO disclosed
WO-2024120467-A1 PHOSPHORAMIDATE MONOSACCHARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS SURIO THERAPEUTICS CO. LTD (CN) 2024-06-13 WO disclosed
WO-2024114814-A1 JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS ONQUALITY PHARMACEUTICALS CHINA LTD (CN) 2024-06-06 WO disclosed
WO-2024104422-A1 PHOSPHORUS-CONTAINING COMPOUNDS FOR TREATING INFLAMMATORY BOWEL DIESEASE VIVAVISION BIOTECH, INC. (CN) 2024-05-23 WO disclosed
WO-2024104384-A1 INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS NUCMITO PHARMACEUTICALS CO. LTD. (CN) 2024-05-23 WO disclosed
WO-1999048997-A1 STABILISATION OF ORGANIC MATERIALS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1999-09-30 WO disclosed
US-5883165-A MIXING POLYOLEFIN WITH ORGANIC PHOSPHITE OR PHOSPHONITE AND 3-ARYLBENZOFURANONE; HEATING, MOLDING, FUSION, ROTATING, COOLING AND REMOVAL CIBA SPECIALTY CHEMICALS CORPORATION (US) 1999-03-16 US disclosed
WO-1998055543-A1 POLYMER STABILIZATION DYNEON LLC (US) 1998-12-10 WO disclosed
US-5814692-A PROTECTING POLYMERS AND LUBRICANTS AGAINST THERMAL, OXIDATIVE OR LIGHT-INDUCED DEGRADATION CIBA SPECIALTY CHEMICALS CORPORATION (US) 1998-09-29 US disclosed
WO-1998041524-A1 PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON α-AMINO ALKENES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-09-24 WO disclosed
WO-1998038195-A1 PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON α-AMMONIUM KETONES, IMINIUM KETONES OR AMIDINIUM KETONES AND ARYL BORATES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-09-03 WO disclosed
US-5773631-A PROTECTION OF POLYMERS AND LUBRICANTS AGAINST THERMAL, OXIDATIVE OR LIGHT INDUCED DEGRDATION CIBA SPECIALTY CHEMICALS CORPORATION (US) 1998-06-30 US disclosed
US-5516920-A POLYMER STABILIZERS CIBA-GEIGY CORPORATION (US) 1996-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297540-A1 SULPHONIUM SALT INITIATORS SULT1A1, SULT2A1, NCOA1 ALDH1A1 1081/4885KDM4E 3933/4885L3MBTL1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.